XYTIS Canadian Trademark Information

On Friday, November 4, 2005, a canadian trademark registration was filed for XYTIS by Xytis Pharmaceuticals Limited, *********, **********, ***** ****. The Canadian IP office has given the trademark application number of 1278499. The current status of this trademark filing is Registration cancelled. The XYTIS trademark is filed in the description of Pharmaceutical products, namely, pharmaceutical products for the treatment of psychiatric and neurological disorders namely schizophrenia, cognitive impairment, apathy, depression, bipolar disorders 1 and 2, depression comorbidites with psychiatric disorders, anxiety, including but not limited to generalised anxiety disorder, epilepsy, sleep disorders, drug addiction, namely addiction to cocaine and methamphetamines, memory and learning impairment conditions and attention deficit hyperactivity disorder, preparations for the treatment, alleviation and/or prevention of neurodegenerative or neuroinflammatory disorders, namely Alzheimer's disease, Parkinson's disease and multiple sclerosis, pharmaceutical products for the treatment, alleviation and/or prevention of secondary brain damage, brain swelling and other neuroinflammatory pathologies namely traumatic brain injury, brain oedema, including neurosurgery induced brain oedema, stroke, ischemia, migraine and other forms of neuropathological pain condition, pharmaceutical products for the treatment or alleviation of neuropathic pain, analgesics, anti-inflammatory preparations namely such preparations for use in the treatment or alleviation of rheumatoid arthritis and osteo arthritis, muscle relaxants, anti-emetics, antispasmodic agents, ophthalmic agents namely products for the treatment of retinal and optical neurodegenerative conditions, non-depolarising skeleton neuromuscular blocking agents and preparations for assisting in the cessation of smoking. , Medical testing and development services. , Medical testing and development services. , Pharmaceutical products, namely, pharmaceutical products for the treatment of psychiatric and neurological disorders namely schizophrenia, cognitive impairment, apathy, depression, bipolar disorders 1 and 2, depression comorbidites with psychiatric disorders, anxiety, including but not limited to generalised anxiety disorder, epilepsy, sleep disorders, drug addiction, namely addiction to cocaine and methamphetamines, memory and learning impairment conditions and attention deficit hyperactivity disorder, preparations for the treatment, alleviation and/or prevention of neurodegenerative or neuroinflammatory disorders, namely Alzheimer's disease, Parkinson's disease and multiple sclerosis, pharmaceutical products for the treatment, alleviation and/or prevention of secondary brain damage, brain swelling and other neuroinflammatory pathologies namely traumatic brain injury, brain oedema, including neurosurgery induced brain oedema, stroke, ischemia, migraine and other forms of neuropathological pain condition, pharmaceutical products for the treatment or alleviation of neuropathic pain, analgesics, anti-inflammatory preparations namely such preparations for use in the treatment or alleviation of rheumatoid arthritis and osteo arthritis, muscle relaxants, anti-emetics, antispasmodic agents, ophthalmic agents namely products for the treatment of retinal and optical neurodegenerative conditions, non-depolarising skeleton neuromuscular blocking agents and preparations for assisting in the cessation of smoking. , Medical testing and development services. , Pharmaceutical products, namely, pharmaceutical products for the treatment of psychiatric and neurological disorders namely schizophrenia, cognitive impairment, apathy, depression, bipolar disorders 1 and 2, depression comorbidites with psychiatric disorders, anxiety, including but not limited to generalised anxiety disorder, epilepsy, sleep disorders, drug addiction, namely addiction to cocaine and methamphetamines, memory and learning impairment conditions and attention deficit hyperactivity disorder, preparations for the treatment, alleviation and/or prevention of neurodegenerative or neuroinflammatory disorders, namely Alzheimer's disease, Parkinson's disease and multiple sclerosis, pharmaceutical products for the treatment, alleviation and/or prevention of secondary brain damage, , Pharmaceutical products, namely, pharmaceutical products for the treatment of psychiatric and neurological disorders namely schizophrenia, cognitive impairment, apathy, depression, bipolar disorders 1 and 2, depression comorbidites with psychiatric disorders, anxiety, including but not limited to generalised anxiety disorder, epilepsy, sleep disorders, drug addiction, namely addiction to cocaine and methamphetamines, memory and learning impairment conditions and attention deficit hyperactivity disorder, preparations for the treatment, alleviation and/or prevention of neurodegenerative or neuroinflammatory disorders, namely Alzheimer's disease, Parkinson's disease and multiple sclerosis, pharmaceutical products for the treatment, alleviation and/or prevention of secondary brain damage, brain swelling and other neuroinflammatory pathologies namely traumatic brain injury, brain oedema, including neurosurgery induced brain oedema, stroke, ischemia, migraine and other forms of neuropathological pain condition, pharmaceutical products for the treatment or alleviation of neuropathic pain, analgesics, anti-inflammatory preparations namely such preparations for use in the treatment or alleviation of rheumatoid arthritis and osteo arthritis, muscle relaxants, anti-emetics, antispasmodic agents, ophthalmic agents namely products for the treatment of retinal and optical neurodegenerative conditions, non-depolarising skeleton neuromuscular blocking agents and preparations for assisting in the cessation of smoking. .